NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Company Overview - NewAmsterdam Pharma (NASDAQ: NAMS) is a biotech company focused on developing obicetrapib, a second-generation CETP inhibitor aimed at addressing cardiovascular risk indications [1] Investment Focus - The company targets growth markets, particularly in biotech, and seeks undervalued stocks with significant potential [1] - The investment strategy includes a diverse portfolio ranging from megacap to microcap stocks, primarily in the U.S. market, with occasional interest in European or Canadian stocks [1] Market Position - Obicetrapib is positioned as a potentially best-in-class treatment, indicating a strong competitive edge in the biotech sector [1]